As drug developers pursue increasingly complex therapies, traditional bioanalytical approaches are being put to the test. How ...

Secarna and Lipigon jointly generated candidates for cardiovascular and metabolic diseases in a target validation and drug discovery collaboration Lipigon will continue the development of acquired ...

• Establishing pharmacologically relevant exposure levels and engagement are two key steps in target validation. • There is a need for better biomarkers to objectively measure biological states and ...

Accelerating Drug Discovery with AI and Next-Generation Automation The pharmaceutical industry is currently witnessi ...

Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in ...

Artificial intelligence (AI) is emerging as a transformative tool in drug discovery and development, influencing steps from target identification to clinical trial outcome analyses. Target ...

Zhongyao Ma, PhD, holds a bachelor’s degree in biology from Shanghai Jiao Tong University and a PhD in genetics and developmental biology from the University of Georgia, U.S. His research focused on ...

On June 22, SK Biopharmaceuticals announced at the 2026 BIO International Convention in the United States that it had signed a research and developmen ...

Large language models (LLMs) can be broadly applied across multiple key stages in drug development: (1) Target identification and drug screening. Llama-Gram, GPCR LLM, and ProtChat systems effectively ...

Identifying the mechanisms of action (MOA) driving a drug’s anti-cancer efficacy is critical for its clinical success, guiding the search for its best biomarkers, indications and combinations. Yet, ...

Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...